How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

344 results for

Tipranavir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

of tipranavir/ritonavir or fosamprenavir/ritonavir Subjects receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02951052 Sponsors and Collaborators ViiV

2016 Clinical Trials

102. Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)

of immunosuppressive agents*. *including anti-neoplastic chemotherapy or cytotoxic radiation therapy for cancer, anti-TNF medications, or other immunomodulating agents. History of a solid organ or bone marrow transplant. Have poorly controlled HIV-infection or HIV-infection treated with Lopinavir, Tipranavir, Etravirine or Didanosine. Poorly controlled HIV is defined as HIV RNA > 50 copies/mm^3 (or greater than the lower limit of quantification [LLOQ] of the local HIV RNA assay if the LLOQ is > 50) in the 6 months

2016 Clinical Trials

103. Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

or planned treatment with strong inhibitors (e.g. ketoconazole, clarithromycin, etcetera [etc]) or strong inducers (e.g. carbamazepine, phenytoin, rifampin, phenobarbital, efavirenz, tipranavir, St. John's wort) of cytochrome P450 3A4/5 (a one week wash-out period is necessary for patients who are already on these treatments) Human immunodeficiency virus (HIV) positive with cluster of differentiation 4 (CD4) count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided

2016 Clinical Trials

104. Structural analyses of 2015-updated drug-resistant mutations in HIV-1 protease: an implication of protease inhibitor cross-resistance (Full text)

(Atazanavir-ATV, Darunavir-DRV, Indinavir-IDV, Lopinavir-LPV, Nelfinavir-NFV, Saquinavir-SQV, and Tipranavir-TPV) showed that cross-resistance can develop easily across NFV, SQV, LPV, IDV, and DRV, but not for ATV or TPV. Through estimation of the changes in vibrational entropies caused by each reported mutation, some secondary mutations were found to destabilize protease structure. Our findings provide an insight into the mechanism of PI cross-resistance and may also be useful in guiding the selection

2016 BMC bioinformatics PubMed

105. Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4 (Full text)

of 0.016±0.001 and 204±18 μM, respectively. Methamphetamine-CYP3A4 docking showed that methamphetamine binds to the heme of CYP3A4 in two modes, both leading to N-demethylation. We then studied the effect of methamphetamine binding on PIs with CYP3A4. Our results showed that methamphetamine alters spectral binding of nelfinavir but not the other type I PIs (lopinavir, atazanavir, tipranavir). The change in spectral binding for nelfinavir was observed at both δAmax (0.004±0.0003 vs. 0.0068±0.0001

2016 PloS one PubMed

106. Development of an HPLC–UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients (Full text)

Development of an HPLC–UV assay method for the simultaneous quantification of nine antiretroviral agents in the plasma of HIV-infected patients A new method using high-performance liquid chromatography coupled with ultra violet detection (HPLC-UV) was developed and validated for the simultaneous quantification of atazanavir, dolutegravir, darunavir, efavirenz, etravirine lopinavir, raltegravir, rilpivirine and tipranavir in human plasma. For the first time we reported here the development

2016 Journal of Pharmaceutical Analysis PubMed

107. Incidence and risk factors for liver enzymes elevations in highly treatment-experienced patients switching from enfuvirtide to raltegravir: a sub-study of the ANRS-138 EASIER trial. (Full text)

), and 5 and 1 % (p = 0.14) of patients in the RAL and ENF arms, respectively. The 48-week incidence of grade 2 or more LEE was 11.6 per 100-pts-years for ALT, 24.5 per 100-pts-years for γ-GT and 4.5 per 100-pts-years for ALP, respectively. In the multivariate analysis, tipranavir/ritonavir use (OR 3.66; 95 % CI [1.20-11.1], p = 0.022) and elevated ALT at baseline (OR 10.3; 95 % CI [2.67-39.6], p < 10(-3)) were significantly associated with a grade 2 or more ALT elevation during follow-up.The incidence (...) of LEE was relatively high in these highly treatment-experienced patients switching to a RAL-based regimen. Both tipranavir/ritonavir use and high baseline ALT levels were associated with an increased risk of ALT.ClinicalTrials.gov identifier: NCT00454337.

2016 AIDS research and therapy PubMed

108. US cost effectiveness of darunavir/ritonavir 600/100mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN trial

reverse transcriptase inhibitors (NRTIs), with or without a non-nucleoside reverse transcriptase inhibitor (NNRTI). These were chosen on the basis of each patient’s treatment history and resistance profile. Darunavir 600mg plus ritonavir 100mg, given twice daily, was compared with lopinavir 400mg plus ritonavir 100mg, given twice daily. In both cases, it was assumed that tipranavir plus ritonavir was given if treatment failed. Location/setting USA/primary and secondary care. Methods Analytical (...) In Treatment-Experienced Patients Naive to Lopinavir; TITAN). The data for tipranavir were from the Randomized Evaluation of Strategic Intervention in Multi-drug Resistant Patients with Tipranavir (RESIST) 1 and 2 trials. The long-term transition probabilities were calculated from cohort study data, using assumed regressions. HIV mortality was from international cohort studies and general mortality was from US life tables. The rate of virologic response and the duration of phases of CD4 count response were

2010 NHS Economic Evaluation Database.

109. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA

ritonavir and an optimised background regimen versus control protease inhibitors plus the optimised background regimen. The protease inhibitors included lopinavir boosted with ritonavir, amprenavir, atazanavir, saquinavir, indinavir, nelfinavir, and boosting dosages of ritonavir. Darunavir 600mg plus ritonavir 100mg was given twice daily. If any treatment failed, it was assumed that tipranavir plus ritonavir was given. Location/setting USA/primary and secondary care. Methods Analytical approach (...) in the short-term. The virologic response at 24 weeks from the beginning of each treatment regimen was a key input for the model. Long-term disease progression was from observational studies and other published sources. The efficacy of tipranavir plus ritonavir was from two clinical trials, with a similar patients to those in POWER 1 and 2. Mortality data were from official databases and US life tables. Some assumptions were needed. Monetary benefit and utility valuations: The utility weights were from

2010 NHS Economic Evaluation Database.

110. Cost effectiveness of darunavir/ritonavir 600/100mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK

treatment failed, it was assumed that patients were switched to tipranavir plus ritonavir. Location/setting UK, Belgium, Italy, and Sweden/primary and secondary care. Methods Analytical approach: The analysis used a published US Markov model, in which the health states were defined by ranges of the patients' cluster of differentiation (CD) 4 cell counts. This was adapted for each country. A lifetime horizon was considered. The authors stated that the analysis was carried out from the perspective (...) sources. The efficacy of tipranavir plus ritonavir was from two clinical trials, with similar patients to those of POWER 1 and 2. HIV-related mortality was from the EuroSIDA cohort study database. Country-specific life tables were used. Monetary benefit and utility valuations: The utility values were from a study that transformed European Quality of life (EQ-5D) questionnaire scores, from 21,000 HIV trial participants, into utility weights using a published preference weight method. Measure of benefit

2010 NHS Economic Evaluation Database.

111. Cost effectiveness of darunavir/ritonavir 600/100mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK (Full text)

resistance. Interventions The two treatments were HAART containing darunavir and HAART containing lopinavir. HAART included an optimised background regimen of two or more nucleoside reverse transcriptase inhibitors, with or without a non-nucleoside reverse transcriptase inhibitor. If either treatment failed, patients were given tipranavir plus ritonavir. Location/setting UK, Belgium, Italy, and Sweden/primary and secondary care. Methods Analytical approach: A published Markov model of HIV management (...) , with a lifetime horizon, was used to simulate the treatment options. The authors stated that the analysis was carried out from the perspective of the public payer. Effectiveness data: The clinical inputs were from a selection of relevant studies. The treatment effect and patients’ characteristics were from a subgroup of patients in a phase III clinical trial (TMC114/r In Treatment-Experienced Patients Naive to Lopinavir; TITAN). The data for tipranavir were from two trials (Randomized Evaluation of Strategic

2010 NHS Economic Evaluation Database. PubMed

112. Pityriasis versicolor

drugs that are metabolised by the CYP450. Possible drug interactions include: Antidiabetic drugs — no change in dosing is normally needed, but warn the person to report any unexpected changes in blood glucose levels. There are isolated reports of hypoglycaemia following concurrent use. Antiretroviral drugs — fluconazole increases the levels of nevirapine, ritonavir, and tipranavir. Monitor for signs of increased adverse effects. Avoid doses of fluconazole greater than 200 mg daily. Carbamazepine

2015 NICE Clinical Knowledge Summaries

113. Rezolsta - darunavir / cobicistat

additivity with all nucleoside/nucleotide reverse transcriptase inhibitors, all tested non-nucleoside reverse transcriptase inhibitors. A modest synergistic effect with amprenavir, nelfinavir and ritonavir was observed whereas additive effects were described for the combination with atazanavir, indinavir, lopinavir, saquinavir, and tipranavir and with the fusion inhibitor enfuvirtide. Cobicistat Cobicistat is a structurally modified analogue of the protease inhibitor ritonavir, which is devoid of anti

2014 European Medicines Agency - EPARs

114. Tivicay - dolutegravir

transcriptase inhibitor OBR Optimized background regimen OSS Overall susceptibility score PDVF Protocol defined virologic failure PI Protease inhibitor PIQ Phenotypic inhibitory quotient PK/PD Pharmacokinetic/pharmacodynamic PSS Phenotypic susceptibility score Assessment report EMA/CHMP/772068/2013 Page 4/102 RAL raltegravir RAM Resistance associated mutation RNA Ribonucleic acid RTV ritonavir TLOVR Time to Loss of Virologic Response TDF tenofovir disoproxil fumarate TPV tipranavir UNAIDS Joint United

2014 European Medicines Agency - EPARs

116. Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation

) Posaconazole (Noxafil) Ritonavir (Novir®, Kaletra) Saquinivir (Fortovase, Invirase) Telaprevir (Incivek) Telithromycin (Ketek) Voriconazole (Vfend) Troleandomycin Cobicistat Tipranavir Receiving any medications or substances that are inducers of CYP3A4; use of the following inducers are prohibited =< 7 days prior to registration Strong inducers of CYP3A4/5; > 80% decrease in AUC Avasimibe Carbamazepine (Carbatrol, Epitol, Equetro, Tegretol, Tegretol-XR) Phenytoin (Dilantin, Phenytek) Rifampin (Rifadin) St (...) . John's wort Mitotane Rifabutin Phenobarbital Moderate inducers of CYP3A4/5; 50-80% decrease in AUC Bosentan (Tracleer) Efavirenz (Sustiva) Etravirine (Intelence) Modafinil (Provigil) Nafcillin Genistein Ritonavir Talyiraline Thioridazine Tipranavir Nevirapine (Viramune) Phenobarbital (Luminal) Rifabutin (Mycobutin) Troglitazone Patients currently receiving treatment with any medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched

2015 Clinical Trials

117. Antiviral Pharmacology and Adherence in Drug Users

not recommended per the SOF/LDV prescribing information (e.g., tipranavir and other P-gp inducers, tenofovir disoproxil fumarate plus cobicistat, rosuvastatin, amiodarone) Any medical condition that in the opinion of the investigators will make it challenging to adhere to the study protocol, such as unstable heart disease or cancer Chronic Hepatitis B virus Infection For females, active pregnancy or any intent to become pregnant For both sexes, an unwillingness to use contraception during the study period

2015 Clinical Trials

118. Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.

HIV RNA level. Suitable ARV include: Tenofovir (TDF) and tenofovir alafenamide (TAF) Emtricitabine (FTC) Rilpivirine Dolutegravir Elvitegravir/cobicistat Contraindicated ARV include: Efavirenz 50% reduction in velpatasvir (GS-5816) exposure Didanosine Zidovudine Tipranavir Other ARV agents may be permissible at the time of study commencement pending further drug-drug interaction studies; please discuss with Study Principal Investigator. Exclusion criteria: Subjects who meet any of the exclusion

2015 Clinical Trials

119. A Pre-Op Window Study Evaluating Anti-Proliferative Effects of Atorvastatin on the Endometrium

Are currently taking any hormonal therapy or have been on hormonal therapy in the past 4 weeks Are taking a drug that may significantly interact or influence the metabolism of atorvastatin Concomitant cyclosporine, gemfibrizol, telaprevir, or tipranavir/ritonavir use History of stroke or transient ischemic attack in the preceding 6 months Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff

2015 Clinical Trials

120. 12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

contraindication to the use of RBV, SOF or LDV Currently receiving zidovudine (ZDV), didanosine (ddI), stavudine (d4T) or tipranavir Acute HIV infection defined as the phase immediately following infection during which anti-HIV antibodies are undetectable Known hepatocellular carcinoma Breastfeeding or pregnancy A male participant with a pregnant female partner Receipt of colony stimulating agents, including but not limited to erythropoietin, within 42 days prior to study entry Contacts and Locations Go

2015 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>